Sana Biotechnology, Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
Sana Biotechnology, Inc. (SANA) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $0 for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2022-11-02
- Sana Biotechnology, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2022-09-30 was $0.00.
- Sana Biotechnology, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2021-12-31 was $0.00.
- Sana Biotechnology, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2021-09-30 was $0.00.
- Sana Biotechnology, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2021-06-30 was $0.00.
- Sana Biotechnology, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2021 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-02 | $0.00 10-Q · filed 2022-11-02 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $0.00 derived: sum of 3 quarters · filed 2022-11-02 | $0.00 10-K · filed 2022-03-16 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $0.00 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2021-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |